KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Goodwill (2016 - 2025)

Biomarin Pharmaceutical's Goodwill history spans 17 years, with the latest figure at $196.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Goodwill changed 0.0% year-over-year to $196.2 million, compared with a TTM value of $196.2 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $196.2 million, changed 0.0% over the prior year.
  • Goodwill for Q4 2025 was $196.2 million at Biomarin Pharmaceutical, roughly flat from $196.2 million in the prior quarter.
  • The five-year high for Goodwill was $196.2 million in Q1 2021, with the low at $196.2 million in Q1 2021.
  • Average Goodwill over 5 years is $196.2 million, with a median of $196.2 million recorded in 2021.
  • Biggest YoY gain for Goodwill was 0.0% in 2021; the steepest drop was 0.0% in 2021.
  • Tracing BMRN's Goodwill over 5 years: stood at $196.2 million in 2021, then changed by 0.0% to $196.2 million in 2022, then changed by 0.0% to $196.2 million in 2023, then changed by 0.0% to $196.2 million in 2024, then changed by 0.0% to $196.2 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Goodwill are $196.2 million (Q4 2025), $196.2 million (Q3 2025), and $196.2 million (Q2 2025).